郑华主诊组
肺癌、胸膜间皮瘤、纵隔肿瘤等胸部肿瘤，以及食管、胃肠、肝胆、胰腺等的消化系统肿瘤的诊断与治疗，在肺癌靶向治疗、免疫治疗、脑膜转移的诊治、高龄肺癌的诊治、以及对难治性胸腔积液处理、癌痛的治疗、化放疗导致的恶心呕吐的治疗以及营养支持等方面有丰富的诊疗经验。
主诊组相关信息
一、代表文章
[1] Sheng S, Wu Z, Zheng H, et al. Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer. J Inflamm Res. 2025 Jul 17;18:9343-9353.
[2] Tan J, Zhao D, Wang Q, et al. Whole Exome Sequencing Study Identifies Distinct Characteristics of Transformed Small Cell Lung Cancer With EGFR Mutation Compared to De Novo Small Cell and Primary Non-Small Cell Lung Cancers. Cancer Med. 2025 Apr;14(7):e70838.[通讯作者]
[3] 郑华,赵丹,顾勐,等. EGFR突变非小细胞肺癌治疗后发生小细胞肺癌转化的临床特征及预后分析[J].中华医学杂志,2024,104(40)：3751-3756.
[4] 吴朝真,郑华,盛舒言,等. 新辅助免疫联合化疗在非小细胞肺癌中的初步疗效观察[J]. 首都医科大学学报,2024,45(4):642-648.
[5] 盛舒言,胡瑛. 脑转移瘤免疫相关疗效评价标准的研究进展[J]. 中国肺癌杂志,2021,24(2):124-130. DOI:10.3779/j.issn.1009-3419.2021.101.03.
[6] Wu Z, Zhang S, Li L, et al. The gut microbiota modulates responses to anti-PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors. Front Oncol. 2022 Oct 25;12:887383.
[7] Wu Z, Tao H, Zhang S, et al. Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting. Cancer Immunol Immunother. 2021 Oct;70(10):2971-2980.
[8] Zheng H, Zeltsman M, Zauderer MG, et al. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy. 2017 Sep;9(11):913-927.
[9] Qu Y, Emoto K, Eguchi T, Aly RG, Zheng H, et al. Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. J Thorac Oncol. 2019 Mar;14(3):482-493.
[10] Zheng H, Zhang H, Zhang T, et al. Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review. Exp Ther Med. 2016 Sep;12(3):1287-1292.
[11] Zheng H, Wang Q, Shi H, et al. Favorable response to icotinib in a lung cancer patient with a special mutation at exon 19 of epidermal growth factor receptor. Thorac Cancer. 2014 Jul;5(4):358-61.
二、科研课题
1.非小细胞肺癌恶性胸腔积液免疫因子改变对抗血管靶向治疗疗效的影响。研究所能力提升项目 2019.9-2022.8
2.晚期非小细胞肺癌EGFR-TKI耐药后小细胞肺癌转化的分子机制研究。北京市通州区科技计划项目 2020.1-2020.12
3. 晚期非小细胞肺癌免疫组库状态与化疗或免疫治疗疗效相关性研究。北京行通州区运河计划领军人才项目 2021.1-2025.12
